BACKGROUND: Under usual care, people with an implantable cardioverter-defibrillator (ICD), cardiac resynchronization therapy with or without a defibrillator (CRT-D and CRT-P, respectively), or a permanent pacemaker have follow-up in-person clinic visits. Remote monitoring of these devices allows the transfer of the information stored in the device so that it can be accessed by the clinic personnel via a secured website. METHODS: We completed a health technology assessment, which included an evaluation of clinical benefits and harms, value for money, and patient preferences for remote monitoring of ICDs, CRTs, and permanent pacemakers plus clinic visits compared with clinic visits alone. This is an update of a 2012 health technology assessment. In addition to the eligible randomized controlled trials (RCTs) from the 2012 publication, we included RCTs identified through a systematic literature search on June 1, 2017. We assessed the risk of bias of each study using the Cochrane risk of bias tool and the quality of the body of evidence according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group criteria. We conducted an economic evaluation to determine the cost-effectiveness of remote monitoring blended with in-clinic follow-up compared to in-clinic follow-up alone in patients with an ICD, a CRT-D, or a pacemaker. We determined the budget impact of blended remote monitoring in patients implanted with ICD, CRT-D, CRT-P, or pacemaker devices from the perspective of the Ontario Ministry of Health and Long-Term Care. To understand patient experiences with remote monitoring, we interviewed 16 patients and family members. RESULTS: Based on 15 RCTs in patients with implanted ICDs or CRT-Ds, remote monitoring plus clinic visits resulted in fewer patients with inappropriate ICD shocks within 12 to 37 months of follow-up (moderate quality evidence; absolute risk difference -0.04 [95% confidence interval -0.07 to -0.01]), fewer total clinic visits (moderate quality evidence), and a shorter time to detection and treatment of events (moderate quality evidence) compared with clinic visits alone. There was a similar risk of major adverse events (moderate quality evidence).Based on 6 RCTs in patients with pacemakers, remote monitoring plus clinic visits reduced the arrhythmia burden (high quality evidence), the time to detection and treatment of arrhythmias (high quality evidence), and the number of clinic visits (moderate quality evidence]) compared with clinic visits alone. Here again, there was a similar risk of major adverse events (high quality evidence).Results from the economic evaluation showed that among ICD and CRT-D recipients, blended remote monitoring (remote monitoring plus in-clinic follow ups) was more costly (incremental value of $4,354 per person) and more effective, providing higher quality-adjusted life years (incremental value of 0.19), compared to in-clinic follow-up alone. Among pacemaker recipients, blended remote monitoring was less costly (with an incremental saving of $2,370 per person) and more effective (with an incremental value of 0.12 quality-adjusted life years) than with in-clinic follow-up alone. We estimated that publicly funding remote monitoring could result in cost savings of $14 million over the first five years.Participants using remote monitoring reported that these devices provide important medical and safety benefits in managing their heart condition. Remote cardiac monitoring provides patients and their family members with an increased freedom. Their belief that the device will help with earlier detection of technical or clinical problems reduces the amount of stress and distraction their condition causes in their lives. CONCLUSIONS: Remote monitoring of ICDs, CRT-Ds, and pacemakers plus clinic visits resulted in improved outcomes without increasing the risk of major adverse events compared with clinic visits alone. Remote monitoring is a cost-effective option for patients implanted with cardiac electronic devices. Patients reported positive experiences using remote monitoring, and perceived that the device provided important medical and safety benefits.
BACKGROUND: Under usual care, people with an implantable cardioverter-defibrillator (ICD), cardiac resynchronization therapy with or without a defibrillator (CRT-D and CRT-P, respectively), or a permanent pacemaker have follow-up in-person clinic visits. Remote monitoring of these devices allows the transfer of the information stored in the device so that it can be accessed by the clinic personnel via a secured website. METHODS: We completed a health technology assessment, which included an evaluation of clinical benefits and harms, value for money, and patient preferences for remote monitoring of ICDs, CRTs, and permanent pacemakers plus clinic visits compared with clinic visits alone. This is an update of a 2012 health technology assessment. In addition to the eligible randomized controlled trials (RCTs) from the 2012 publication, we included RCTs identified through a systematic literature search on June 1, 2017. We assessed the risk of bias of each study using the Cochrane risk of bias tool and the quality of the body of evidence according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group criteria. We conducted an economic evaluation to determine the cost-effectiveness of remote monitoring blended with in-clinic follow-up compared to in-clinic follow-up alone in patients with an ICD, a CRT-D, or a pacemaker. We determined the budget impact of blended remote monitoring in patients implanted with ICD, CRT-D, CRT-P, or pacemaker devices from the perspective of the Ontario Ministry of Health and Long-Term Care. To understand patient experiences with remote monitoring, we interviewed 16 patients and family members. RESULTS: Based on 15 RCTs in patients with implanted ICDs or CRT-Ds, remote monitoring plus clinic visits resulted in fewer patients with inappropriate ICD shocks within 12 to 37 months of follow-up (moderate quality evidence; absolute risk difference -0.04 [95% confidence interval -0.07 to -0.01]), fewer total clinic visits (moderate quality evidence), and a shorter time to detection and treatment of events (moderate quality evidence) compared with clinic visits alone. There was a similar risk of major adverse events (moderate quality evidence).Based on 6 RCTs in patients with pacemakers, remote monitoring plus clinic visits reduced the arrhythmia burden (high quality evidence), the time to detection and treatment of arrhythmias (high quality evidence), and the number of clinic visits (moderate quality evidence]) compared with clinic visits alone. Here again, there was a similar risk of major adverse events (high quality evidence).Results from the economic evaluation showed that among ICD and CRT-D recipients, blended remote monitoring (remote monitoring plus in-clinic follow ups) was more costly (incremental value of $4,354 per person) and more effective, providing higher quality-adjusted life years (incremental value of 0.19), compared to in-clinic follow-up alone. Among pacemaker recipients, blended remote monitoring was less costly (with an incremental saving of $2,370 per person) and more effective (with an incremental value of 0.12 quality-adjusted life years) than with in-clinic follow-up alone. We estimated that publicly funding remote monitoring could result in cost savings of $14 million over the first five years.Participants using remote monitoring reported that these devices provide important medical and safety benefits in managing their heart condition. Remote cardiac monitoring provides patients and their family members with an increased freedom. Their belief that the device will help with earlier detection of technical or clinical problems reduces the amount of stress and distraction their condition causes in their lives. CONCLUSIONS: Remote monitoring of ICDs, CRT-Ds, and pacemakers plus clinic visits resulted in improved outcomes without increasing the risk of major adverse events compared with clinic visits alone. Remote monitoring is a cost-effective option for patients implanted with cardiac electronic devices. Patients reported positive experiences using remote monitoring, and perceived that the device provided important medical and safety benefits.
Authors: Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori Journal: N Engl J Med Date: 2001-05-31 Impact factor: 91.245
Authors: Derek V Exner; David H Birnie; Gordon Moe; Bernard Thibault; François Philippon; Jeffrey S Healey; Anthony S L Tang; Éric Larose; Ratika Parkash Journal: Can J Cardiol Date: 2013-02 Impact factor: 5.223
Authors: Matthew Bennett; Ratika Parkash; Pablo Nery; Mario Sénéchal; Blandine Mondesert; David Birnie; Laurence D Sterns; Claus Rinne; Derek Exner; François Philippon; Debra Campbell; Jafna Cox; Paul Dorian; Vidal Essebag; Andrew Krahn; Jaimie Manlucu; Franck Molin; Michael Slawnych; Mario Talajic Journal: Can J Cardiol Date: 2016-10-06 Impact factor: 5.223
Authors: Gerhard Hindricks; Niraj Varma; Salem Kacet; Thorsten Lewalter; Peter Søgaard; Laurence Guédon-Moreau; Jochen Proff; Thomas A Gerds; Stefan D Anker; Christian Torp-Pedersen Journal: Eur Heart J Date: 2017-06-07 Impact factor: 29.983
Authors: Giuseppe Boriani; Antoine Da Costa; Renato Pietro Ricci; Aurelio Quesada; Stefano Favale; Saverio Iacopino; Francesco Romeo; Arnaldo Risi; Lorenza Mangoni di S Stefano; Xavier Navarro; Mauro Biffi; Massimo Santini; Haran Burri Journal: J Med Internet Res Date: 2013-08-21 Impact factor: 5.428
Authors: Shiqiang Xiong; Jin Li; Lin Tong; Jun Hou; Siqi Yang; Lingyao Qi; Xu Chen; Yan Luo; Zhen Zhang; Hanxiong Liu; Lin Cai Journal: Front Cardiovasc Med Date: 2022-05-16
Authors: Shannon E Kelly; Debra Campbell; Lenora J Duhn; Karen Giddens; Anne M Gillis; Amir AbdelWahab; Isabelle Nault; Satish R Raj; Evan Lockwood; Jessica Basta; Steve Doucette; George A Wells; Ratika Parkash Journal: CJC Open Date: 2020-11-20
Authors: Shannon E Kelly; Tammy J Clifford; Doug Coyle; Janet Martin; Vivian Welch; Becky Skidmore; David Birnie; Ratika Parkash; Anthony S L Tang; George A Wells Journal: Syst Rev Date: 2020-06-27
Authors: Remedios López-Liria; Antonio López-Villegas; César Leal-Costa; Salvador Peiró; Emilio Robles-Musso; Rafael Bautista-Mesa; Patricia Rocamora-Pérez; Knut Tore Lappegård; Daniel Catalán-Matamoros Journal: Int J Environ Res Public Health Date: 2020-02-23 Impact factor: 3.390
Authors: John A Sapp; Anne M Gillis; Amir AbdelWahab; Isabelle Nault; Pablo B Nery; Jeff S Healey; Satish R Raj; Evan Lockwood; Laurence D Sterns; Samuel F Sears; George A Wells; Raymond Yee; François Philippon; Anthony Tang; Ratika Parkash Journal: CMAJ Open Date: 2021-01-25
Authors: Rafael Jesus Bautista-Mesa; Antonio Lopez-Villegas; Salvador Peiro; Daniel Catalan-Matamoros; Emilio Robles-Musso; Remedios Lopez-Liria; Cesar Leal-Costa Journal: BMC Geriatr Date: 2020-11-16 Impact factor: 3.921
Authors: Kam Cheong Wong; Tu N Nguyen; Simone Marschner; Samual Turnbull; Mason Jenner Burns; Jia Yi Anna Ne; Vishal Gopal; Anupama Balasuriya Indrawansa; Steven A Trankle; Tim Usherwood; Saurabh Kumar; Richard I Lindley; Clara K Chow Journal: JMIR Res Protoc Date: 2022-02-01